Tetralogy of fallot interventions: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Tetralogy of fallot}} {{CMG}}; {{AE}} {{Fs}} ==Overview== There are no recommended therapeutic interventions for the management of [disease name]. OR [Name of i..." |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Fs}} | {{CMG}}; {{AE}} {{Fs}} | ||
== | == 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines<ref name="pmid30121240">{{cite journal| author=Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM | display-authors=etal| title=2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. | journal=J Am Coll Cardiol | year= 2019 | volume= 73 | issue= 12 | pages= 1494-1563 | pmid=30121240 | doi=10.1016/j.jacc.2018.08.1028 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30121240 }}</ref> == | ||
=== Therapeutic Recommendations for Tetralogy of Fallot === | |||
{| class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen" |[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen" |'''1.'''Pulmonary valve replacement (surgical or percutaneous) for relief of symptoms is recommended for patients with repaired TOF and moderate or greater PR with cardiovascular symptoms not otherwise explained. ''(Level of Evidence: B-NR)'' | |||
|} | |||
{| class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon" |[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
| bgcolor="LemonChiffon" |'''1.'''Pulmonary valve replacement (surgical or percutaneous) is reasonable for preservation of ventricular size and function in asymptomatic patients with repaired TOF and ventricular enlargement or dysfunction and moderate or greater PR. ''(Level of Evidence: B-NR)'' | |||
|- | |||
| bgcolor="LemonChiffon" |'''2.''' Primary prevention ICD therapy is reasonable in adults with TOF and multiple risk factors for SCD. (''Level of Evidence: B-NR)'' | |||
|} | |||
{| class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon" |[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | |||
|- | |||
| bgcolor="LemonChiffon" |'''1.''' Surgical pulmonary valve replacement may be reasonable for adults with repaired TOF and moderate or greater PR with other lesions requiring surgical interventions'''.''' ''(Level of Evidence: C-EO)'' | |||
|- | |||
| bgcolor="LemonChiffon" |'''2.''' Pulmonary valve replacement, in addition to arrhythmia management, may be considered for adults with repaired TOF and moderate or greater PR and ventricular tachyarrhythmia. ''(Level of Evidence: C-EO)'' | |||
|} | |||
==Indications== | ==Indications== | ||
Latest revision as of 08:29, 16 December 2022
|
Tetralogy of fallot Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
|
|
Tetralogy of fallot interventions On the Web |
|
American Roentgen Ray Society Images of Tetralogy of fallot interventions |
|
Risk calculators and risk factors for Tetralogy of fallot interventions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[1]
Therapeutic Recommendations for Tetralogy of Fallot
| Class I |
| 1.Pulmonary valve replacement (surgical or percutaneous) for relief of symptoms is recommended for patients with repaired TOF and moderate or greater PR with cardiovascular symptoms not otherwise explained. (Level of Evidence: B-NR) |
| Class IIa |
| 1.Pulmonary valve replacement (surgical or percutaneous) is reasonable for preservation of ventricular size and function in asymptomatic patients with repaired TOF and ventricular enlargement or dysfunction and moderate or greater PR. (Level of Evidence: B-NR) |
| 2. Primary prevention ICD therapy is reasonable in adults with TOF and multiple risk factors for SCD. (Level of Evidence: B-NR) |
| Class IIb |
| 1. Surgical pulmonary valve replacement may be reasonable for adults with repaired TOF and moderate or greater PR with other lesions requiring surgical interventions. (Level of Evidence: C-EO) |
| 2. Pulmonary valve replacement, in addition to arrhythmia management, may be considered for adults with repaired TOF and moderate or greater PR and ventricular tachyarrhythmia. (Level of Evidence: C-EO) |
Indications
The mainstay of treatment for TT is medical therapy.
References
- ↑ Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM; et al. (2019). "2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". J Am Coll Cardiol. 73 (12): 1494–1563. doi:10.1016/j.jacc.2018.08.1028. PMID 30121240.